Skip to main content

Beatriz Minguez Rosique

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Beatriz Minguez Rosique

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Malalties Hepatobiliars (GRC)

IP: -
Collaborators: Beatriz Minguez Rosique, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Antonio González Fernández, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Silvia Sauleda Oliveras, Maria Buti Ferret, Josep Quer Sivila, Josep Gregori Font, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Juan Ignacio Esteban Mur, Meritxell Ventura Cots, Macarena Simon-Talero Horga, Joan Genescà Ferrer, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 65000
Reference: 2014 SGR 421
Duration: 01/01/2014 - 31/12/2016

Lipotoxicity, Hepatic Steatosis and Hepatocarcinoma: role of the Armc10/Armcx family of mitochondrial proteins

IP: Beatriz Minguez Rosique
Collaborators: Monica Higuera Urbano
Funding agency: Fundació La Marató de TV3
Funding: 98437.5
Reference: 20133732
Duration: 14/03/2014 - 13/03/2017

Terapia molecular del carcinoma hepatocelular mediante inhibición de las vías de señalización PI3K/AKT y EFGR

IP: -
Collaborators: Beatriz Minguez Rosique
Funding agency: Ministerio de Educación, Cultura y Deporte
Funding:
Reference: FULBRIGHT_01_2008
Duration: 01/12/2008 - 30/11/2009

Efectos de la infusión de albúmina en el episodio de encefalopatía hepática. Estudio aleatorio y multicéntrico en pacientes con cirrosis hepática

IP: -
Collaborators: Beatriz Minguez Rosique, Meritxell Ventura Cots
Funding agency: Instituto de Salud Carlos III
Funding: 71390
Reference: PI070641
Duration: 01/01/2008 - 30/12/2011

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Related professionals

David Gurwitz

David Gurwitz

Senior researcher
Systemic Diseases
Read more
SILVIA GARTNER TIZZANO

SILVIA GARTNER TIZZANO

Main researcher
Growth and Development
Read more
Luca Basile

Luca Basile

Administration and Management
Microbiology
Read more
Ana  Leon  Espitia

Ana Leon Espitia

Predoctoral researcher
Research Group of Physical Medicine and Rehabilitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.